Getting Answers: The Path to a Diagnosis

Getting to a diagnosis of Familial Partial Lipodystrophy Type 5 (FPLD5) often feels like solving a complex puzzle. Because it is so rare, it is frequently mistaken for more common conditions like Type 2 diabetes or Metabolic Syndrome ^[1]. However, while those conditions are often linked to a high Body Mass Index (BMI), FPLD5 is a “plumbing problem” of fat storage that can cause severe metabolic disease even in people with a near-normal weight ^[1][2].

The Clinical Suspicion: A “Phenotype-Led” Approach

Doctors usually begin the diagnostic process by looking at your phenotype—the physical characteristics and symptoms your body displays ^[3]. Unlike common obesity, where fat is stored all over the body, FPLD5 follows a specific pattern. A doctor might suspect FPLD if you have ^[4][5]:

• Visible Fat Loss: Noticeable thinning of the fat under the skin on your arms and legs (lipoatrophy) ^[4].
• “Metabolic Disproportion”: Severe insulin resistance, extremely high triglycerides, or fatty liver disease that seems “out of sync” with your overall body weight ^[1].
• Skin Clues: Darkened, velvety skin (acanthosis nigricans) or signs of excess male-pattern hormones (hirsutism), which are markers of high insulin ^[5].

Imaging: Mapping Your Fat Distribution

To move beyond a visual “hunch,” doctors use specialized imaging to objectively measure where your body stores fat. These tests can support the diagnosis or document body composition, though there is no universally validated FPLD5 imaging threshold, and they are not required for every patient.

• DXA (Dual-Energy X-ray Absorptiometry): While often used for bone density, a “whole-body composition” DXA can create a “fat shadow” map ^[6]. It can quantify the trunk-to-leg fat ratio, which may show very low fat percentages in the limbs despite higher fat in the torso ^[7][8].
• MRI (Magnetic Resonance Imaging): A whole-body or regional MRI provides a detailed look at fat depots ^[9]. In FPLD5, an MRI might show ectopic fat stored in the liver or muscles, and a lack of the “cushioning” fat typically found under the skin or around the buttocks ^[10][5]. Depending on the clinical question, ultrasound or targeted tests might be used instead.

The Decisive Step: Genetic Testing

The only way to definitively confirm FPLD5 is through genetic testing ^[11]. This is usually done using a lipodystrophy gene panel, which tests dozens of genes known to cause fat storage disorders, including the CIDEC gene ^[12].

For a diagnosis of FPLD5, the test must find biallelic variants ^[5]. Since this is an autosomal recessive condition, this means:

1. Homozygous: You have two identical mutations in the CIDEC gene (one from each parent).
2. Compound Heterozygous: You have two different mutations in the CIDEC gene. These two variants need to be shown to be in trans (on opposite copies of the gene, meaning one was inherited from each parent). This is often confirmed through parental testing.

Reading Your Genetic Report

When you receive your genetic report, look for these specific details to discuss with your specialist or a genetic counselor:

• Gene: It should list CIDEC ^[5].
• Zygosity: This tells you if you have one copy (heterozygous, typically a carrier) or two copies (homozygous or compound heterozygous, meaning you have the condition) ^[5].
• Classification: Variants are often labeled as Pathogenic (known to cause disease), Likely Pathogenic, or VUS (Variant of Uncertain Significance) ^[13]. A VUS means the mutation is rare, but researchers aren’t yet certain it causes the condition ^[13]. Rarity alone does not establish pathogenicity, and a VUS should not be used by itself to confirm the diagnosis or guide predictive testing for relatives. A negative panel or a VUS does not completely exclude a clinically suspected lipodystrophy.